Alpha-1 Antitrypsin and Survival in Liver Cancer
Author Information
Author(s): A. Tzonoul, L. Sparosi, V. Kalapothakil, X. Zavitsanos, A. Rebelakos, D. Trichopoulos
Primary Institution: University of Athens Medical School
Hypothesis
Is there an association between serum levels of alpha-1 antitrypsin at diagnosis and survival in patients with hepatocellular carcinoma?
Conclusion
Higher serum levels of alpha-1 antitrypsin at diagnosis are associated with shorter survival in patients with hepatocellular carcinoma.
Supporting Evidence
- Patients with higher serum alpha-1 antitrypsin levels had a shorter expected survival time.
- Older patients and those positive for HBsAg had higher fatality rates.
- The median survival time for patients was 6 months.
Takeaway
This study found that if a patient has high levels of a protein called alpha-1 antitrypsin when diagnosed with liver cancer, they might not live as long.
Methodology
The study followed 78 patients with hepatocellular carcinoma and analyzed the relationship between serum alpha-1 antitrypsin levels and survival using Cox's proportional hazards model.
Potential Biases
Potential biases may arise from the observational nature of the study and the reliance on historical data.
Limitations
The study only included patients from one geographical area and may not be generalizable to other populations.
Participant Demographics
All participants were Caucasian, of Greek nationality, with an average age of 63 years, and 87% were male.
Statistical Information
P-Value
0.05
Confidence Interval
579-652 mg 100 ml-
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website